Search

Displaying results 8131 - 8140 of 10000 in total
  1. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.

  2. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. … The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.

  3. Drug

    Vintafolide

    go.drugbank.com/drugs/DB05168
    Investigational

    Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.

    Categories: Heterocyclic Compounds, 2-Ring
  4. Drug

    Benzimate

    go.drugbank.com/drugs/DB05170
    Experimental

    Benzimate is the lead compound selected from a series of compounds known as benzimidazoles. … It is currently under investigation by AmpliMed and is in phase I of clinical trial.

  5. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    It is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  6. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.

    Synonyms: N-adamantanyl-N'-geranyl-ethylenediamineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  7. Drug

    Atl146e

    go.drugbank.com/drugs/DB05191
    Investigational

    ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.

    Categories: Adenosine A receptor agonists, Heterocyclic Compounds, 2-Ring
  8. Drug

    Ordopidine

    go.drugbank.com/drugs/DB05196
    Investigational

    ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.

  9. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. … Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. … LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system